Related Experiment Video

Updated: May 11, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade:

P Queirolo1, A Morabito, S Laurent

  • 1UOC Oncologia Medica A, IRCCS A.O.U. San Martino-IST, Genova, Italy.

Cancer Investigation
|May 7, 2013
PubMed

Insights

Certain CTLA-4 gene variations are linked to better survival in metastatic melanoma patients treated with immunotherapy. These findings may help personalize cancer treatment strategies.

Area of Science:

  • Immunogenetics
  • Oncology

Background:

  • Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) blockade using monoclonal antibodies shows efficacy in metastatic melanoma (MM).
  • The influence of CTLA-4 gene polymorphisms on patient response to anti-CTLA-4 therapy is not well-established.

Purpose of the Study:

  • To investigate the association between CTLA-4 single nucleotide polymorphisms (SNPs) and clinical outcomes in Italian patients with metastatic melanoma.

Main Methods:

  • Genotyping of six CTLA-4 SNPs (-1661A > G, -1577G > A, -658C > T, -319C > T, +49A > G, and CT60G > A) was performed.
  • Analysis included 14 Italian MM patients and 45 healthy controls.
  • Statistical analysis, including Bonferroni correction and diplotype analysis, was employed.

Main Results:

  • A significant association was found between the -1577G/A and CT60G/A genotypes and improved overall survival (Pc < 0.006).
  • Diplotype analysis of the -1577 & CT60 GG-AA diplotype confirmed this association (p < 0.001).
  • A trend towards an association between these genotypes and therapy response was observed.

Conclusions:

  • Specific CTLA-4 gene polymorphisms (-1577G/A and CT60G/A) are associated with enhanced overall survival in metastatic melanoma patients.
  • These genetic markers may serve as predictive factors for immunotherapy response.
  • Further research is warranted to validate these findings and explore their clinical utility.

More Related Videos

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.